← Back to headlines
Eli Lilly and InSilico Partner for AI-Powered Drug Discovery
Pharmaceutical giant Eli Lilly has entered into a strategic agreement with InSilico, a company specializing in artificial intelligence, to collaborate on AI-driven drug discovery initiatives, aiming to accelerate the development of new medicines.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
